Sylatron Dosage

Generic name: peginterferon alfa-2b
Dosage form: injection

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Recommended Dosing

  • The recommended starting dose is 6 mcg/kg/week subcutaneously for 8 doses, followed by 3 mcg/kg/week subcutaneously for up to 5 years.
  • Premedicate with acetaminophen 500 to 1000 mg orally 30 minutes prior to the first dose of SYLATRON and as needed for subsequent doses.
  • The recommended starting doses of SYLATRON in patients with moderate or severe renal impairment or end-stage renal disease (ESRD) are listed in Table 1 [see Use in Specific Populations (8.7)]. No dose adjustment is needed for patients with a creatinine clearance (CLcr) > 50 mL/min/1.73m2.
Table 1: Recommended Starting Dose for Moderate and Severe Renal Impairment and End-Stage Renal Disease
Degree of Renal Impairment Creatinine Clearance (mL/min/1.73m2) Initial doses for 8 weeks Follow-up doses for 5 years
Moderate 30 – 50 4.5 mcg/kg/week 2.25 mcg/kg/week
Severe <30 3 mcg/kg/week 1.5 mcg/kg/week
End-Stage Renal Disease On dialysis 3 mcg/kg/week 1.5 mcg/kg/week

Dose Modification Guidelines

Guidelines for Dose Modification provided below are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE Version 2.0).

  • Permanently discontinue SYLATRON for:
    • Persistent or worsening severe neuropsychiatric disorders
    • Grade 4 non-hematologic toxicity
    • Inability to tolerate a dose of 1 mcg/kg/wk
    • New or worsening retinopathy
  • Withhold SYLATRON dose for any of the following:
    • Absolute Neutrophil Count (ANC) less than 0.5×109/L
    • Platelet Count (PLT) less than 50×109/L
    • ECOG PS greater than or equal to 2
    • Non-hematologic toxicity greater than or equal to Grade 3
  • Resume dosing at a reduced dose (see Table 1) when all of the following are present:
    • Absolute Neutrophil Count (ANC) greater than or equal to 0.5×109/L
    • Platelet Count (PLT) greater than or equal to 50×109/L
    • ECOG PS 0–1
    • Non-hematologic toxicity has completely resolved or improved to Grade 1
Table 2: SYLATRON Dose Modifications
Starting Dose Dose Modifications for Doses 1 to 8
6 mcg/kg/week   First Dose Modification: 3 mcg/kg/week
  Second Dose Modification: 2 mcg/kg/week  
  Third Dose Modification: 1 mcg/kg/week  
  Permanently discontinue if unable to tolerate 1 mcg/kg/week  
 
Starting Dose Dose Modifications for Doses 9 to 260
3 mcg/kg/week   First Dose Modification: 2 mcg/kg/week
  Second Dose Modification: 1 mcg/kg/week  
  Permanently discontinue if unable to tolerate 1 mcg/kg/week  

Preparation and Administration

Reconstitute SYLATRON with 0.7 mL of Sterile Water for Injection, USP.

Table 3: Reconstitution of SYLATRON Single-Use Vials
SYLATRON
Single-Use Vial
Diluent (Sterile Water for Injection, USP) Deliverable Product and Volume Final Concentration
*
Total vial content of SYLATRON is 296 mcg.
Total vial content of SYLATRON is 444 mcg.
Total vial content of SYLATRON is 888 mcg.
200 mcg* add 0.7 mL = 200 mcg in 0.5 mL 40 mcg/0.1 mL
300 mcg add 0.7 mL = 300 mcg in 0.5 mL 60 mcg/0.1 mL
600 mcg add 0.7 mL = 600 mcg in 0.5 mL 120 mcg/0.1 mL
  • Swirl gently to dissolve the lyophilized powder. DO NOT SHAKE.
  • Visually inspect the solution for particulate matter and discoloration prior to administration. Discard if solution is discolored, cloudy, or if particulates are present.
  • Do not withdraw more than 0.5 mL of reconstituted solution from each vial.
  • Administer SYLATRON subcutaneously. Rotate injection sites.
  • If reconstituted solution is not used immediately, store at 2°–8°C (36°–46°F) for no more than 24 hours. Discard reconstituted solution after 24 hours. DO NOT FREEZE.
  • For single-use only. DISCARD ANY UNUSED PORTION.
Hide
(web3)